U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.

Cover of Drugs and Lactation Database (LactMed®)

Drugs and Lactation Database (LactMed®) [Internet].

Show details


Last Revision: December 3, 2018.

Estimated reading time: 3 minutes

CASRN: 88150-42-9

Chemical structure

Drug Levels and Effects

Summary of Use during Lactation

Limited information indicates that milk levels of amlodipine are usually low and plasma levels in breastfed infants are undetectable. Maternal use of amlodipine during breastfeeding has not caused any adverse effects in breastfed infants. If amlodipine is required by the mother, it is not a reason to discontinue breastfeeding.

Drug Levels

Maternal Levels. Thirty-one postpartum women with pregnancy-induced hypertension received amlodipine 5 mg daily by mouth, with the dosage increased as needed to maintain blood pressure of 140/90 mm Hg or less. The final mean dosage for the group was 6 mg (0.099 mg/kg) daily. Simultaneous predose maternal blood and breastmilk samples were obtained within 3 weeks postpartum, after at least 6 days of therapy. The median milk concentration was 11.5 mcg/L (intraquartile range 9.8 to 18 mcg/L). The authors calculated a median infant dosage of 4.2 mcg/kg (intraquartile range 3.1 to 6.3 mcg/kg), which corresponds to a weight-adjusted maternal dosage of 4.2% (intraquartile range 3.1 to 7.3%). However, using the median milk concentration, one would calculate an infant dosage of only 1.73 mcg/kg daily and a weight-adjusted relative dosage of 1.7%. It is unclear why the difference exists between reported and calculate values. In 5 mothers, the weight-adjusted maternal dosage was above 10%, with a maximum value of 15.2% in one mother.[1] All of these calculations are suboptimal because only single points of maternal plasma and milk concentrations were measured rather than using an area-under-the-curve to calculate them.

Six mothers were taking amlodipine 5 mg daily during pregnancy and postpartum. On the second day postpartum, 6 colostrum samples were obtained at 4, 6, 8, 12, 15 and 24 hours following the dose. Amlodipine was undetectable (<0.1 mcg/L) in all samples.[2]

Eight mothers with infants 5 to 7 days old were taking amlodipine 2.5 mg (1 subject) or 5 mg (7 subjects) daily. They donated foremilk samples at various times after the dose. Peak concentrations in milk occurred from 4 to 8 hours after a dose and ranged from 8 to 20 mcg/L in 5 women with more than 4 milk samples. The weight-adjusted maternal dosage averaged 3.3% (range 1.6% to 4.3%) among the 8 mothers.[3]

Infant Levels. A preterm infant of 32 weeks gestation was breastfed exclusively from day 7 to day 20 postpartum. The infant's mother was taking amlodipine and labetalol in unspecified dosages for hypertension. After 4 days of breastfeeding, the infant's blood amlodipine level was unmeasurable (lower limit of assay not specified).[4]

Eight infants whose mothers were taking amlodipine 5 mg daily during pregnancy had blood samples taken at 24 to 48 hours postpartum. Amlodipine concentrations were unmeasurable (<0.1 mcg/L) in all samples, although the paper does not state how many of the infants were being breastfed.[2]

Nine infants aged 5 to 7 days were exclusively breastfed by 8 mothers who were taking amlodipine 2.5 mg (1 mother) or 5 mg (7 mothers) daily. Blood samples were taken from the infants before and after nursing at 8 hours after their mothers' amlodipine dose. All infant blood levels were undetectable (<0.4 mcg/L).[3]

Effects in Breastfed Infants

A woman took amlodipine for hypertension 5 mg daily beginning 2 weeks postpartum. Her exclusively breastfed infant was examined regularly and at 3 months of age was healthy and had normal physical and neurological development.[5]

One woman received amlodipine 2.5 mg orally twice daily during pregnancy for hypertension associated with glomerulonephritis. The dose was increased to 5 mg twice daily on day 2 postpartum. Her exclusively breastfed infant's growth was normal throughout the first year of life and no adverse effects were noted.[6]

A preterm infant of 32 weeks gestation was breastfed exclusively from day 7 to day 20 postpartum. The infant's mother was taking amlodipine and labetalol in unspecified dosages for hypertension. The infant had apnea episodes unrelated to amlodipine. Growth at 2 months of age was slightly low.[4]

Thirty-one women with pregnancy-induced hypertension postpartum received amlodipine 5 mg daily by mouth, with the dosage increased as needed to maintain blood pressure of 140/90 mm Hg or less. Their breastfed (extent not stated) infants exhibited no observed adverse cardiovascular effects within 3 weeks postpartum, although exact measurement methods were not stated.[1]

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Nifedipine, Nitrendipine


Naito T, Kubono N, Deguchi S et al. Amlodipine passage into breast milk in lactating women with pregnancy-induced hypertension and its estimation of infant risk for breastfeeding. J Hum Lact. 2015;31:301-6. [PubMed: 25447596]
Morgan JL, Kogutt BK, Meek C et al. Pharmacokinetics of amlodipine besylate at delivery and during lactation. Pregnancy Hypertens. 2018;11:77-80. [PMC free article: PMC5846630] [PubMed: 29523279]
Aoki H, Ito N, Kaniwa N et al. Low levels of amlodipine in breast milk and plasma. Breastfeed Med. 2018;13:622-6. [PubMed: 30265578]
Vasa R, Martha Ramirez M. Amlodipine exposure through breastfeeding in a 32 week preterm newborn. Breastfeeding Med. 2013;8 (Suppl 1):S15. Abstract. DOI: 10.1089/bfm.2013.9982. [CrossRef]
Ahn HK, Nava-Ocampo AA, Han JY et al. Exposure to amlodipine in the first trimester of pregnancy and during breastfeeding. Hypertens Pregnancy. 2007;26:179-87. [PubMed: 17469008]
Szucs KA, Axline SE, Rosenman MB. Maternal membranous glomerulonephritis and successful exclusive breastfeeding. Breastfeed Med. 2010;5:123-6. [PubMed: 20491564]

Substance Identification

Substance Name


CAS Registry Number


Drug Class

  • Breast Feeding
  • Antihypertensive Agents
  • Calcium Channel Blockers
  • Vasodilator Agents

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Copyright Notice

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Bookshelf ID: NBK500665PMID: 29999724


Related information

Similar articles in PubMed

  • Identification and characterization of potential impurities of amlodipine maleate.[J Pharm Biomed Anal. 2006]
    Identification and characterization of potential impurities of amlodipine maleate.
    Sudhakar P, Nirmala M, Moses Babu J, Vyas K, Madhusudan Reddy G, Vijaya Bhaskar B, Pratap Reddy P, Mukkanti K. J Pharm Biomed Anal. 2006 Feb 24; 40(3):605-13. Epub 2005 Dec 1.
  • Review Nicardipine.[Drugs and Lactation Database (...]
    Review Nicardipine.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Felodipine.[Drugs and Lactation Database (...]
    Review Felodipine.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Nitrendipine.[Drugs and Lactation Database (...]
    Review Nitrendipine.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Meperidine.[Drugs and Lactation Database (...]
    Review Meperidine.
    . Drugs and Lactation Database (LactMed®). 2006
See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...